Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study - PubMed (original) (raw)
Clinical Trial
. 2007 Jan 23;49(3):290-7.
doi: 10.1016/j.jacc.2006.08.054. Epub 2007 Jan 8.
Affiliations
- PMID: 17239709
- DOI: 10.1016/j.jacc.2006.08.054
Free article
Clinical Trial
Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study
Markolf Hanefeld et al. J Am Coll Cardiol. 2007.
Free article
Abstract
Objectives: The purpose of this study was to test the safety and efficacy of pioglitazone and simvastatin in combination versus each drug individually in non-diabetic subjects with cardiovascular disease (CVD) and elevated high-sensitivity C-reactive protein (hs-CRP) levels.
Background: Low-grade inflammation is a pathogenic factor for atherosclerosis. High-sensitivity CRP, matrix metalloproteinase (MMP)-9, and plasminogen activator inhibitor (PAI)-1 are markers of inflammation. Statins and peroxisome proliferator-activated receptor (PPAR)-gamma agonists lower inflammatory markers and reduce CVD in type 2 diabetes.
Methods: In a 12-week, prospective, double-blind trial, 125 subjects were randomized to simvastatin or pioglitazone plus placebo or a simvastatin/pioglitazone combination. We tested changes in hs-CRP by analysis of covariance. A subgroup analysis was performed in patients with and without the metabolic syndrome (MetS). The correlation between changes in hs-CRP and homeostasis model assessment (HOMA; a measure of insulin resistance) was calculated with the Spearman's rank test.
Results: At baseline, there were no significant between-group differences. At 12 weeks, pioglitazone and simvastatin monotherapies significantly reduced hs-CRP (3.64 +/- 2.42 mg/l to 2.48 +/- 1.77 mg/l and 3.26 +/- 2.02 mg/l to 2.81 +/- 2.11 mg/l) and the combination regimen had an additive effect (from 3.49 +/- 1.97 mg/l to 2.06 +/- 1.42 mg/l, p < 0.001). For subgroups, the difference between monotherapy and combination therapy was only significant for simvastatin versus simvastatin plus pioglitazone in patients without MetS. Homeostasis model assessment decreased in those receiving pioglitazone, and the correlation between changes in HOMA and hs-CRP was significant (r = 0.43; p < 0.05). The PAI-1 decreased significantly in the pioglitazone groups only, and MMP-9 was also significantly lowered in the pioglitazone groups. No treatment-related serious adverse events occurred in any group.
Conclusions: Pioglitazone, probably by reducing insulin resistance, has additive anti-inflammatory effects to simvastatin in non-diabetic subjects with CVD and high hs-CRP.
Similar articles
- Effects of pioglitazone versus simvastatin on biomarkers of inflammation in patients on high cardiovascular risk.
Hanefeld M, Schaper F, Appelt D, Fuchs W. Hanefeld M, et al. Horm Metab Res. 2011 Dec;43(13):980-3. doi: 10.1055/s-0031-1291233. Epub 2011 Nov 8. Horm Metab Res. 2011. PMID: 22068809 Clinical Trial. - Peroxisome proliferator-activated receptor-gamma activation with pioglitazone improves endothelium-dependent dilation in nondiabetic patients with major cardiovascular risk factors.
Campia U, Matuskey LA, Panza JA. Campia U, et al. Circulation. 2006 Feb 14;113(6):867-75. doi: 10.1161/CIRCULATIONAHA.105.549618. Epub 2006 Feb 6. Circulation. 2006. PMID: 16461819 Clinical Trial. - Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.
Chu CS, Lee KT, Lee MY, Su HM, Voon WC, Sheu SH, Lai WT. Chu CS, et al. Am J Cardiol. 2006 Mar 1;97(5):646-50. doi: 10.1016/j.amjcard.2005.09.101. Epub 2006 Jan 9. Am J Cardiol. 2006. PMID: 16490430 Clinical Trial. - Effects of pioglitazone on lipid and lipoprotein metabolism.
Betteridge DJ. Betteridge DJ. Diabetes Obes Metab. 2007 Sep;9(5):640-7. doi: 10.1111/j.1463-1326.2007.00715.x. Diabetes Obes Metab. 2007. PMID: 17697057 Review. - C-reactive protein: a new risk assessment tool for cardiovascular disease.
Clearfield MB. Clearfield MB. J Am Osteopath Assoc. 2005 Sep;105(9):409-16. J Am Osteopath Assoc. 2005. PMID: 16239491 Review.
Cited by
- A pilot study of circulating PPAR-γ receptor protein in elderly patients with atrial fibrillation.
Lin Q, Jia L, Sun Y. Lin Q, et al. Arch Med Sci. 2012 Jul 4;8(3):471-6. doi: 10.5114/aoms.2012.29402. Arch Med Sci. 2012. PMID: 22852002 Free PMC article. - Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment.
Triplitt C, Cersosimo E, DeFronzo RA. Triplitt C, et al. Vasc Health Risk Manag. 2010 Sep 7;6:671-90. doi: 10.2147/vhrm.s4852. Vasc Health Risk Manag. 2010. PMID: 20859539 Free PMC article. Review. - Pioglitazone and sulfonylureas: effectively treating type 2 diabetes.
Hanefeld M. Hanefeld M. Int J Clin Pract Suppl. 2007 Jun;61(153):20-7. doi: 10.1111/j.1742-1241.2007.01361.x. Int J Clin Pract Suppl. 2007. PMID: 17594390 Free PMC article. Review. - Double-blind, randomized, multicentre, and active comparator controlled investigation of the effect of pioglitazone, metformin, and the combination of both on cardiovascular risk in patients with type 2 diabetes receiving stable basal insulin therapy: the PIOCOMB study.
Hanefeld M, Pfützner A, Forst T, Kleine I, Fuchs W. Hanefeld M, et al. Cardiovasc Diabetol. 2011 Jul 14;10:65. doi: 10.1186/1475-2840-10-65. Cardiovasc Diabetol. 2011. PMID: 21756323 Free PMC article. Clinical Trial. - Effects of Combination Therapy of Statin and Thiazolidinedione on Vascular Inflammation.
Lee JY, Cha BS. Lee JY, et al. Korean Circ J. 2018 Jul;48(7):602-604. doi: 10.4070/kcj.2018.0120. Korean Circ J. 2018. PMID: 29968432 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous